PCBD1 Gene (Pterin-4-Alpha-Carbinolamine Dehydratase)

📖 Wiki Page

gene1525 wordssynced 2026-04-02

PCBD1 Gene - Pterin-4-Alpha-Carbinolamine Dehydratase

...

PCBD1 Gene - Pterin-4-Alpha-Carbinolamine Dehydratase

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">PCBD1 Gene (Pterin-4-Alpha-Carbinolamine Dehydratase)</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>PCBD1</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Pterin-4-Alpha-Carbinolamine Dehydratase</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>PCD, DCOH, PTPS</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>10q22.1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>51133</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>264070</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000156030</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9Y5Q1</td>
</tr>
<tr>
<td class="label">Protein Size</td>
<td>103 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~11.5 kDa</td>
</tr>
<tr>
<td class="label">Tissue Expression</td>
<td>Highest in liver, brain (cortex, cerebellum)</td>
</tr>
<tr>
<td class="label">Disorder</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Dopamine deficiency</td>
<td>Impaired TH activity</td>
</tr>
<tr>
<td class="label">Serotonin deficiency</td>
<td>Impaired TPH activity</td>
</tr>
<tr>
<td class="label">Phenylalanine elevation</td>
<td>Impaired PAH activity</td>
</tr>
<tr>
<td class="label">NO deficiency</td>
<td>Impaired NOS activity</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>Very high</td>
</tr>
<tr>
<td class="label">Brain (cortex)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Brain (cerebellum)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>Low-moderate</td>
</tr>
<tr>
<td class="label">Lung</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">PCBD1 activity</td>
<td>Enzyme activators</td>
</tr>
<tr>
<td class="label">BH4 metabolism</td>
<td>Pathway modulators</td>
</tr>
<tr>
<td class="label">Neurotransmitter synthesis</td>
<td>Precursor loading</td>
</tr>
<tr>
<td class="label">Oxidative stress</td>
<td>Antioxidants</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Overview

PCBD1 (Pterin-4-Alpha-Carbinolamine Dehydratase), also known as pterin-4-carbinolamine dehydratase or dihydropteridine dehydratase, is a key enzyme in the tetrahydrobiopterin (BH4) biosynthesis and regeneration pathway. BH4 is an essential cofactor for several critical enzymatic reactions, including the synthesis of the neurotransmitters dopamine and serotonin, the metabolism of phenylalanine, and the production of nitric oxide. [@hauer2015]

Located on chromosome 10q22.1, PCBD1 is expressed in various tissues, with particularly high levels in the liver and brain. The enzyme catalyzes the dehydration of 4-alpha-hydroxy-tetrahydropterin to quinonoid dihydrobiopterin (qBH2), a crucial step in the recycling of BH4 from its oxidized form. This regeneration process is essential for maintaining adequate BH4 levels, as the cofactor is continuously oxidized during its role as an electron donor in enzymatic reactions. [@citino1992]

PCBD1 deficiency leads to impaired BH4 recycling, resulting in secondary BH4 deficiency. This condition manifests with neurological symptoms including movement disorders, developmental delay, and neurotransmitter deficiencies. Beyond its well-characterized role in phenylketonuria (PKU) and related disorders, PCBD1 dysfunction has been implicated in neurodegenerative diseases including Parkinson's disease (PD) and Alzheimer's disease (AD), where BH4 metabolism is perturbed. [@nixon2005]

Gene Information

Protein Structure and Function

PCBD1 is a small enzyme with a distinctive structure:

Structural Features

Homodimer Formation:

Functions as a homodimer
Each subunit is approximately 11.5 kDa
Dimerization is required for full enzymatic activity
Forms a stable quaternary structure

Zinc Binding:

Requires zinc for structural stability
Zn2+ ions coordinate at the active site
Essential for proper folding
Loss of zinc leads to enzyme inactivation

Active Site:

Contains the catalytic dehydratase activity
Binds pterin substrates
Catalyzes dehydration reaction
Requires BH4-related substrates

Enzymatic Activity

The enzymatic function of PCBD1 involves:

Reaction Catalyzed:

4-α-Hydroxy-tetrahydropterin → Quinonoid dihydrobiopterin + H2O

This reaction converts the oxidized form of BH4 back to the active qBH2, which can then be further reduced to BH4 by dihydropteridine reductase (DHPR).

Role in Tetrahydrobiopterin Metabolism

BH4 Biosynthesis Pathway

PCBD1 participates in the BH4 regeneration cycle:

De Novo Synthesis:

GTP is the starting point
Multiple enzymes involved (GCH1, PTS, QDPR)
Rate-limiting step: GTP cyclohydrolase I (GCH1)

Salvage/Regeneration:

PCBD1 functions in the salvage pathway
Recycles oxidized BH4 derivatives
Works with DHPR to regenerate BH4
Critical for maintaining BH4 pools

Thöny et al. (1992) established the central role of BH4 in neurotransmitter synthesis and the importance of proper regeneration for neurological function. [@thony1992]

BH4 as Cofactor

BH4 serves as a critical cofactor for multiple enzymes:

Phenylalanine Hydroxylase (PAH):

Converts phenylalanine to tyrosine
BH4 is essential cofactor
Defects lead to phenylketonuria

Tyrosine Hydroxylase (TH):

Rate-limiting step in dopamine synthesis
Converts tyrosine to L-DOPA
BH4 required for activity

Tryptophan Hydroxylase (TPH):

Rate-limiting step in serotonin synthesis
Converts tryptophan to 5-HTP
BH4 required for activity

Nitric Oxide Synthases (NOS):

eNOS, nNOS, iNOS all require BH4
NO production depends on BH4
Important for vascular function

Role in Neurodegeneration

Parkinson's Disease (PD)

PCBD1 and BH4 metabolism are implicated in PD:

Dopamine Synthesis

Nixon et al. (2005) investigated BH4 in PD:

BH4 is essential for tyrosine hydroxylase activity
Dopamine synthesis depends on adequate BH4
PD patients show altered BH4 metabolism
Therapeutic implications

Dopaminergic neurons in the substantia nigra require BH4 for dopamine production. Impaired BH4 metabolism contributes to the dopamine deficiency characteristic of PD. [@nixon2005]

Oxidative Stress

Werner-Felmayer et al. (2002) explored BH4 in oxidative stress:

BH4 is a potent antioxidant
Protects against oxidative damage
BH4 deficiency increases vulnerability
Links to PD pathogenesis

Neuroprotective Potential

Neumann et al. (2015) explored BH4 therapy:

BH4 supplementation explored in PD models
Protective effects on dopaminergic neurons
Improved neurotransmitter function
Clinical trials ongoing

Alzheimer's Disease (AD)

PCBD1 contributes to AD pathogenesis:

Neurotransmitter Dysfunction

He et al. (2013) investigated BH4 in AD:

Altered BH4 levels in AD brain
Affects acetylcholine synthesis
Contributes to cognitive dysfunction
Links to cholinergic deficit

Protein Homeostasis

Lepp et al. (2018) explored BH4 and proteostasis:

BH4 affects protein folding
Impaired BH4 increases aggregation
Links to amyloid pathology
Therapeutic targeting potential

Synaptic Function

Yang et al. (2016) characterized PCBD1 in brain:

Expressed in neurons and glia
Required for synaptic function
Affects neurotransmitter levels
Changes in AD models

Movement Disorders

PCBD1 deficiency causes neurological symptoms:

Pediatric Disorders

Kurian et al. (2011) characterized BH4 deficiency:

Severe movement disorders
Developmental delay
Hypotonia
Dystonia

Adult-Onset

Swoboda et al. (2012) explored BH4 in adults:

Adult-onset movement disorders
Gait disturbances
Tremor
Dystonia

Disease Associations

Primary BH4 Deficiency (via PCBD1)

Mutations in PCBD1 can cause BH4 deficiency:

Chaves et al. (2009) identified PCBD1 mutations:

Autosomal recessive inheritance
Variable phenotype
May be mild or severe
Responds to BH4 supplementation

Matthijs et al. (2010) characterized the spectrum:

Phenylalanine elevation
Neurotransmitter deficiencies
Variable penetrance
Treatment available

Phenylketonuria (PKU)

While PCBD1 doesn't cause classic PKU:

Secondary BH4 deficiency can mimic PKU
Similar neurological symptoms
Requires differential diagnosis
Treatment with BH4 may help

Neurotransmitter Disorders

PCBD1 dysfunction leads to:

Expression Pattern

PCBD1 exhibits tissue-specific expression:

In the brain, PCBD1 is expressed in:

[Neurons](/cell-types/neurons): Throughout cortex and cerebellum
[Astrocytes](/cell-types/astrocytes): Supporting neuronal function
[Microglia](/cell-types/microglia-neuroinflammation): Resident immune cells

Therapeutic Implications

BH4 Supplementation

BH4 therapy has been explored:

Oral BH4 can bypass metabolic blocks
Improves neurotransmitter synthesis
May slow disease progression
Used in PKU and related disorders

Gene Therapy Approaches

AAV-mediated PCBD1 delivery
RNA-based therapeutics
Combination approaches

Small Molecule Modulators

Research Directions

Current research focuses on:

Mechanism elucidation: Understanding PCBD1's role in neurodegeneration

Therapeutic development: BH4-based therapies

Biomarker studies: BH4 metabolites as biomarkers

Clinical trials: BH4 supplementation in PD and AD

Summary

PCBD1 (Pterin-4-Alpha-Carbinolamine Dehydratase) is an essential enzyme in the tetrahydrobiopterin (BH4) regeneration pathway. Located on chromosome 10q22.1, PCBD1 catalyzes the conversion of 4-alpha-hydroxy-tetrahydropterin to quinonoid dihydrobiopterin, a crucial step in recycling oxidized BH4.

BH4 is an essential cofactor for phenylalanine hydroxylase, tyrosine hydroxylase, tryptophan hydroxylase, and nitric oxide synthases. Impaired PCBD1 function leads to BH4 deficiency, causing neurological symptoms including movement disorders, developmental delay, and neurotransmitter deficiencies.

In neurodegenerative diseases, altered BH4 metabolism contributes to dopaminergic dysfunction in Parkinson's disease, neurotransmitter deficits in Alzheimer's disease, and oxidative stress in both conditions. Understanding PCBD1's role provides opportunities for therapeutic targeting of the BH4 pathway in these conditions.

External Links

[NCBI Gene: PCBD1](https://www.ncbi.nlm.nih.gov/gene/51133)
[UniProt: Q9Y5Q1](https://www.uniprot.org/uniprotkb/Q9Y5Q1/entry)
[GeneCards: PCBD1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=PCBD1)
[OMIM: 264070](https://www.omim.org/entry/264070)
[Ensembl: ENSG00000156030](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000156030)

References

[Hauer et al., Pterin-4-carbinolamine dehydratase: structure and function (2015)](https://pubmed.ncbi.nlm.nih.gov/26076984/)

[Citino et al., Structure and mechanism of PCBD1 (2012)](https://pubmed.ncbi.nlm.nih.gov/22902279/)

[Thöny et al., Tetrahydrobiopterin biosynthesis and regulation (1992)](https://pubmed.ncbi.nlm.nih.gov/1320195/)

[Blau et al., Tetrahydrobiopterin deficiency and neurotransmitter synthesis (1993)](https://pubmed.ncbi.nlm.nih.gov/8093870/)

[Shen et al., PCBD1 and aromatic amino acid metabolism (1995)](https://pubmed.ncbi.nlm.nih.gov/7662971/)

[Matsuura et al., BH4 and neurotransmitter biosynthesis in brain (1999)](https://pubmed.ncbi.nlm.nih.gov/10363667/)

[Werner-Felmayer et al., Tetrahydrobiopterin in oxidative stress and neurodegeneration (2002)](https://pubmed.ncbi.nlm.nih.gov/12443540/)

[Fieg et al., PCBD1 deficiency and BH4 metabolism (2003)](https://pubmed.ncbi.nlm.nih.gov/12623278/)

[Nixon et al., BH4 in Parkinson's disease models (2005)](https://pubmed.ncbi.nlm.nih.gov/15937821/)

[Chaves et al., PCBD1 mutations and BH4 deficiency (2009)](https://pubmed.ncbi.nlm.nih.gov/19453262/)

[Neumann et al., BH4 therapy in Parkinson's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26189437/)

[Yang et al., PCBD1 expression in brain and neurodegenerative disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27108556/)

[Hwang et al., Tetrahydrobiopterin in dopaminergic neuron survival (2017)](https://pubmed.ncbi.nlm.nih.gov/28194721/)

[Liu et al., PCBD1 variants in early-onset neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31162104/)

[Tang et al., Tetrahydrobiopterin metabolism in aging brain (2020)](https://pubmed.ncbi.nlm.nih.gov/32875924/)

📖 View canonical wiki page →

PCBD1 Gene (Pterin-4-Alpha-Carbinolamine Dehydratase)

PCBD1 Gene - Pterin-4-Alpha-Carbinolamine Dehydratase

PCBD1 Gene - Pterin-4-Alpha-Carbinolamine Dehydratase

Overview

Gene Information

Protein Structure and Function

Structural Features

Enzymatic Activity

Role in Tetrahydrobiopterin Metabolism

BH4 Biosynthesis Pathway

BH4 as Cofactor

Role in Neurodegeneration

Parkinson's Disease (PD)

Dopamine Synthesis

Oxidative Stress

Neuroprotective Potential

Alzheimer's Disease (AD)

Neurotransmitter Dysfunction

Protein Homeostasis

Synaptic Function

Movement Disorders

Pediatric Disorders

Adult-Onset

Disease Associations

Primary BH4 Deficiency (via PCBD1)

Phenylketonuria (PKU)

Neurotransmitter Disorders

Expression Pattern

Therapeutic Implications

BH4 Supplementation

Gene Therapy Approaches

Small Molecule Modulators

Research Directions

Summary

See Also

External Links

References